Apollomics (APLMW) News Today

$0.03
0.00 (0.00%)
(As of 04/26/2024 ET)
SourceHeadline
globenewswire.com logoApollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
globenewswire.com - April 25 at 8:30 AM
globenewswire.com logoApollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
globenewswire.com - April 10 at 7:00 AM
globenewswire.com logoApollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
globenewswire.com - March 28 at 7:00 AM
globenewswire.com logoApollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
globenewswire.com - March 4 at 7:00 AM
Get Apollomics News Delivered to You Automatically

Sign up to receive the latest news and ratings for APLMW and its competitors with MarketBeat's FREE daily newsletter.

They say it’s ‘unstoppable’ – How I made 43,509% (Ad)

Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.

Click here now for the full story.

APLMW Media Mentions By Week

APLMW Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

APLMW
News Sentiment

0.50

0.32

Average
Medical
News Sentiment

APLMW News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

APLMW Articles
This Week

2

0

APLMW Articles
Average Week

Get Apollomics News Delivered to You Automatically

Sign up to receive the latest news and ratings for APLMW and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:APLMW) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners